Daniel Faga
CIK 1673528 · President, CEO · last filed 2026-05-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$47.15M
Companies
4
Total Filings
38
Lifetime Open-Market Net
-$9.41M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRAX | President, CEO | 496,684 | $41.85 | $20.79M | $0 | 2 | 2026-05-14 |
| ANAB | President, CEO | 505,862 | $52.11 | $26.36M | -$6.34M | 15 | 2026-04-23 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | EVP, Chief Operating Officer | 30,638 | $58.70 | $1.80M | -$828.3K | 4 | 2021-02-03 |
| Spark Therapeutics, Inc. (ONCE) Delisted | Chief Business Officer | 0 | — | — | -$2.23M | 14 | 2019-12-17 |
Recent Filings · Page 3 of 4
38 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-02-03 | Mirati Therapeutics, Inc. (MRTX) Delisted | Mixed | — | -$107.3K | EDGAR |
| 2021-01-20 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +7,023 | $0 | EDGAR |
| 2021-01-08 | Mirati Therapeutics, Inc. (MRTX) Delisted | Sell (S) | −2,625 | -$567.9K | EDGAR |
| 2020-01-08 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +26,240 | $0 | EDGAR |
| 2019-12-17 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | −38,828 | -$4.45M | EDGAR |
| 2019-03-27 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | +34,796 | -$3.47M | EDGAR |
| 2019-01-23 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | +2,911 | -$71.6K | EDGAR |
| 2019-01-17 | Spark Therapeutics, Inc. (ONCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-22 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | +1,121 | -$44.4K | EDGAR |
| 2017-10-24 | Spark Therapeutics, Inc. (ONCE) Delisted | Mixed | — | -$325.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.